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Abstract	Objectives:	We	assessed	the	current	genetic	evidence	for	the	involvement	of	various	cell	types	and	tissue	types	in	the	aetiology	of	neurodegenerative	diseases,	especially	in	relation	to	the	neuroinflammatory	hypothesis	of	neurodegenerative	diseases.		Methods:	We	obtained	large-scale	genome-wide	association	study	(GWAS)	summary	statistics	from	Parkinson’s	disease	(PD),	Alzheimer’s	disease	(AD),	and	amyotrophic	lateral	sclerosis	(ALS).	We	used	multiple	sclerosis	(MS),	an	autoimmune	disease	of	the	central	nervous	system,	as	a	positive	control.	We	applied	stratified	LD	score	regression	to	determine	if	functional	marks	for	cell	type	and	tissue	activity,	and	gene	set	lists	were	enriched	for	genetic	heritability.	We	compared	our	results	to	those	from	two	gene-set	enrichment	methods	(Ingenuity	Pathway	Analysis	and	enrichr).		Results:	There	were	no	significant	heritability	enrichments	for	annotations	marking	genes	active	within	brain	regions,	but	there	were	for	annotations	marking	genes	active	within	cell-types	that	form	part	of	both	the	innate	and	adaptive	immune	systems.		We	found	this	for	MS	(as	expected)	and	also	for	AD	and	PD.	The	strongest	signals	were	from	the	adaptive	immune	system	(e.g.	T	cells)	for	PD,	and	from	both	the	adaptive	(e.g.	T	cells)	and	innate	(e.g.	CD14:	a	marker	for	monocytes,	and	CD15:	a	marker	for	neutrophils)	immune	systems	for	AD.	Annotations	from	the	liver	were	also	significant	for	AD.	Pathway	analysis	provided	complementary	results.	
	Interpretation:		For	Alzheimer’s	and	Parkinson’s	disease,	we	found	significant	enrichment	of	heritability	in	annotations	marking	gene	activity	in	immune	cells.		
	
Introduction	Neurodegenerative	diseases	–	including	Alzheimer’s	(AD),	amyotrophic	lateral	sclerosis	(ALS),	and	Parkinson’s	disease	(PD)	–	are	personally	devastating	and	an	increasing	burden	on	health-care	systems	worldwide.	Recently	there	has	been	much	progress	in	identifying	genetic	variants	associated	with	neurodegenerative	diseases.	In	the	latest	AD	meta-analysis	19	loci	in	addition	to	the	well-established	APOE	locus	were	pinpointed.1	The	latest	ALS	meta-analysis	identified	three	ALS-associated	loci2	and	the	latest	PD	meta-analysis	brought	the	total	number	of	established	PD	loci	to	26.3	Despite	progress	in	identifying	genetic	hits	in	these	neurodegenerative	diseases,	the	underlying	processes	or	cell-types	mediating	the	pathology	remain	uncertain.		As	genome-wide	association	studies	(GWASs)	have	grown	in	size	and	power,	so	has	the	quality	and	scope	of	functional	information	that	can	be	used	to	annotate	the	genome	with	relevant	genomic	and	epigenomic	marks	linked	to	the	regulation	of	gene	expression.		Previous	studies	have	demonstrated	enrichment	of	disease-associated	variants	(for	numerous	diseases)	with	functional	genomic	annotations,	including	DNase	I	hypersensitive	sites,	transcription	factor	binding	sites,	histone	modifications,	and	expression	quantitative	trait	loci	(eQTLs).4–7	These	annotations	vary	depending	on	cell/tissue-type.	Given	the	many	ways	in	which	complex	diseases	
arise,	and	for	human	brain	diseases,	the	well-recognized	cellular	heterogeneity	of	the	brain,	pinpointing	cell-types	of	interest	is	important	to	further	understand	pathogenicity.	Efforts	to	obtain	brain	samples	(the	most	obviously	relevant	tissue	for	neurodegenerative	diseases)	for	eQTL	analyses	are	ongoing.8–13	There	has	been	a	recent	proliferation	in	the	availability	of	cell-type	and	tissue-specific	annotations,	including	brain	tissue,	for	example	through	the	Roadmap	Epigenomics	Project14	and	the	PsychEncode	Project.11	Nevertheless,	obtaining	large	numbers	of	post-mortem	human	brains	remains	challenging,	and	current	eQTL	analyses	are	likely	to	be	underpowered.	Characterization	of	eQTLs	and	DNA	regulatory	elements	in	blood	is	a	complementary	approach.		The	neuroinflammatory	hypothesis	of	neurodegenerative	diseases	posits	that	dysregulation	of	the	immune	system	is	an	important	factor	in	the	aetiology	of	these	diseases.15,16	There	is	little	doubt	that	multiple	sclerosis	(MS)	is	an	immune-mediated	disease17	18,19	We	therefore	use	this	disease	as	a	positive	control	with	regard	to	expected	enrichment	in	heritability	for	annotations	from	immune	cells.	There	is	extensive	functional	and	clinical	evidence	that	immune	dysfunction	plays	a	key	role	in	the	pathogenesis	of	the	relapse-remitting	phase	of	MS.20,21	For	AD,	Yokoyama	et	al.22	showed	that	eight	variants	were	associated	with	both	AD	and	immune-mediated	diseases,	and	there	is	further	evidence	from	pathway	analysis1,23,24	and	from	animal	models.25	For	PD,	the	role	of	the	immune	system	has	been	suggested	through	pathway	analysis26,27,	animal	models28,	and	variants	in	the	HLA	region	reaching	statistical	significance	in	genome-wide	association	studies.3,29	For	ALS,	there	is	evidence	of	immune	abnormalities.30	Nevertheless,	the	extent	to	which	the	immune	system	is	involved	in	neurodegenerative	diseases	such	as	AD,	ALS	and	PD,	and	the	potential	roles	played	by	the	innate	and	adaptive	immune	components,	remain	unestablished.				Finucane	et	al.31	introduced	stratified	LD	score	regression	as	a	method	for	partitioning	the	inferred	heritability	from	GWAS	summary	statistics.	They	determined	whether	genetic	heritability	in	17	GWASs	was	enriched	within	various	functional	annotations	which	reflected	parts	of	the	genome	that	were	active	in	a	number	of	tissues	and	cell-types.	We	applied	this	methodology	to	four	diseases	(MS,	AD,	ALS,	PD)	to	test	for	enrichment	of	heritability,	both	using	Finucane	et	al.’s31	cell-type	group	annotations	and	using	additional	annotations	from	brain	and	immune	cells	and	from	published	sets	of	brain	and	immune-related	genes.32	 
Methods		We	obtained	GWAS	summary	statistics	for	three	neurodegenerative	diseases:	AD,1	ALS2	and	PD.3	We	used	MS33	as	a	positive	control,	as	it	is	a	disease	affecting	the	brain	with	known	immune	aetiology.	All	studies	were	conducted	in	European	populations,	and	are	summarized	in	Table	1.	For	AD,	which	is	a	two-stage	study,	we	only	used	data	from	the	first	stage.	(See	Box	1	for	details	on	this	study.)	We	did	not	study	Huntington’s	disease	(which	has	other	genetic	modifiers	in	addition	to	the	primary	
HTT	locus)	and	frontotemporal	dementia,	because	the	current	GWAS	sample	sizes	
for	these	diseases	are	modest,	and	thus	the	datasets	were	considered	to	be	insufficiently	powered	for	our	analyses.31			
Box	1.	International	Genomics	of	Alzheimer's	Project	(IGAP)	is	a	large	two-stage	study	based	upon	genome-wide	association	studies	(GWAS)	on	individuals	of	European	ancestry.	In	stage	1,	IGAP	used	genotyped	and	imputed	data	on	7,055,881	single	nucleotide	polymorphisms	(SNPs)	to	meta-analyse	four	previously-published	GWAS	datasets	consisting	of	17,008	Alzheimer's	disease	cases	and	37,154	controls	(The	European	Alzheimer's	disease	Initiative	–	EADI	the	Alzheimer	Disease	Genetics	Consortium	–	ADGC	The	Cohorts	for	Heart	and	Aging	Research	in	Genomic	Epidemiology	consortium	–	CHARGE	The	Genetic	and	Environmental	Risk	in	AD	consortium	–	GERAD).	In	stage	2,	11,632	SNPs	were	genotyped	and	tested	for	association	in	an	independent	set	of	8,572	Alzheimer's	disease	cases	and	11,312	controls.	Finally,	a	meta-analysis	was	performed	combining	results	from	stages	1	&	2.		We	estimated	pairwise	genetic	correlations	among	the	four	diseases	using	cross-trait	LD	score	regression.34	We	then	applied	stratified	LD	score	regression	to	determine	if	various	functional	categories		(cell-type	groups,	annotations	at	the	tissue/cell	level	for	brain	or	immune	cells,	and	sets	of	brain	and	immune	gene	lists)	were	enriched	for	heritability.	LD	score	regression	exploits	the	expected	relationships	between	true	association	signals	and	local	LD	around	them	to	correct	out	systematic	biases	and	arrive	at	unbiased	estimates	of	genetic	heritability	within	a	given	set	of	SNPs	(here	stratified	according	to	their	functional	category).31	Following	Finucane	et	al.31,	we	added	annotations	individually	to	the	baseline	model;	we	used	HapMap	Project	Phase	3	SNPs	for	the	regression	and	1000	Genomes	Project	European	population	SNPs	for	the	reference	panel;	we	only	partitioned	the	heritability	of	SNPs	with	minor	allele	frequency	>5%;	and	we	excluded	the	MHC	region	from	analysis.		The	high	LD	and	strong	association	signals	within	the	MHC	region	result	in	a	dominating	effect	on	LD	score	regression,	and	for	the	purposes	of	our	analyses	excluding	this	region	results	in	a	conservative	approach.			The	grouped	cell-type	annotations	provided	by	Finucane	et	al.31	are	the	union	of	histone	marks	for	10	broad	categories	including	central	nervous	system	(CNS),	cardiovascular,	immune/hematopoietic,	and	liver.	For	these	analyses	we	corrected	for	multiple	testing	of	four	GWASs	across	10	cell-type	groups	(4	x	10	=	40	hypotheses	tested),	resulting	in	a	Bonferroni	significance	threshold	of	p=	1.2	x	10-3.		We	then	extended	the	analytical	approach	of	Finucane	et	al.31	in	the	following	ways.	Firstly,	we	obtained	additional	annotation	information.		We	obtained	histone	marks	and	DNase	I	hypersensitive	sites	data	from	the	Roadmap	Epigenomics	Consortium;14	we	obtained	eQTLs	derived	from	brain	regions	from	the	UK	Brain	Expression	Consortium10	and	the	GTEx	Consortium;9	and	we	obtained	promoter	capture	HiC	array	express	data	in	CD34	(a	marker	of	immature	hematopoietic	cells)	cells	from	GM12878	(reference:	E-MTAB-2323).35	We	also	considered	two	gene-
sets.	All	these	annotations	are	listed	in	Supplementary	Table	1.	Secondly,	in	order	to	reduce	the	multiple	testing	burden,	we	combined	information	across	the	four	different	histone	marks	and	the	DNase	I	hypersensitive	marks	in	order	to	create	an	aggregate	set	of	regulatory	marks	for	each	cell	type.	This	aggregation	annotation	was	obtained	based	on	a	simple	union	operation:	for	each	tissue	or	cell-type,	a	SNP	was	labeled	as	‘annotated’	based	on	whether	it	possessed	any	relevant	histone	mark	or	DNase	I	hypersensitive	mark.	Both	DNase	I	and	histone	marks	are	known	to	reflect	active	regions	of	the	genome,	motivating	their	aggregation	in	order	to	create	a	general	mark	of	genomic	activity.	DNase	I	sites	are	associated	with	an	open	chromatin	structure,	and	different	histone	marks	are	markers	of	active	promoters	(H3K4Me3	+	H3K27Ac)	or	active	enhancers	(H3K4Me1	+	H3K27Ac)	regions.		For	brain	tissue,	we	defined	a	union	set	of	histone	marks	plus	DNase	I	hypersensitive	sites	from	the	Roadmap	Epigenomics	Consortium14	using	the	same	aggregation	procedure	as	above.	This	processing	resulted	in	one	annotation	per	brain	region	(10	annotations).		We	grouped	eQTLs	across	all	brain	regions,	but	treated	the	eQTLs	from	the	UK	Brain	Expression	Consortium10	and	the	GTEx	Consortium9	separately	(resulting	in	two	annotations).		Both	the	GTEx	and	UKBEC	analyses	included	brain	regions	highly	relevant	to	MS,	AD	and	PD,	namely	white	matter,	hippocampus,	temporal	cortex	and	substantia	nigra.			Amongst	specific	immune	cells	we	assessed	the	histone	marks	previously	described,31	and	also	the	histone	marks	and	DNase	I	hypersensitive	site	data	from	the	Roadmap	Epigenomics	Consortium	for	immune	and	blood	cells,14	and	we	took	the	union	for	each	cell-type	as	described	above	(three	histone	marks	and	DNase	I	hypersensitive	site).		This	resulted	in	20	annotations	from	Finucane	et	al.31	and	14	annotations	from	Roadmap.			Additionally,	we	defined	four	immune	cell-type	annotations	based	on	promoter	capture	HiC	array	express	data	in	CD34	from	GM12878	(reference:	E-MTAB-2323).35	The	data	for	the	prey	and	bait	were	analysed	separately	for	interactions	between	captured	promoter	and	captured	promoter	interactions	and	for	captured	promoter	and	all	other	regions,	which	resulted	in	four	annotations.		The	above	cell/tissue-type	specific	annotations	resulted	in	a	multiple	testing	correction	for	four	GWASs	across	50	(12	brain	+	38	immune)	annotations	(4	x	50	=	204	hypotheses	tested).	Thus	we	set	a	Bonferroni	significance	threshold	of	p=	2.5	x	10-4	for	these	analyses.		Note	that	there	are	correlations	within	the	immune	and	brain	annotations,	making	our	Bonferroni	correction	somewhat	conservative		We	also	applied	heritability	enrichment	analysis	to	two	sets	of	genes;	one	with	known	brain	and	one	with	known	immune	function.	We	used	a	brain	gene	list	of	2,635	genes	previously	described	by	Raychaudhuri	et	al.36,	and	an	immune	gene	list	of	973	genes	previously	described	by	Pouget	et	al.32	Brain	genes	were	defined	as	
those	fulfilling	any	of	the	following	criteria:	preferential	expression	in	the	brain	compared	to	other	tissues,	“neural-activity”	annotation	in	Panther,	“learning”	annotation	in	Ingenuity,	and	“synapse”	annotation	in	Gene	Ontology.	Immune	genes	were	defined	as	those	with	an	“immune	response”	annotation	in	at	least	three	of	the	following	databases:	Kyoto	Encyclopedia	of	Genes	and	Genomes,	Gene	Ontology,	Ingenuity,	and	Immunology	Database	and	Analysis	Portal.	SNPs	were	annotated	to	genes	using	a	50	kb	window,	and	a	baseline	list	of	all	genes	using	this	50	kb	window	was	included	in	the	model	as	previously	described.32		Finally,	we	contrasted	the	above	heritability	enrichment	analyses	with	a	complementary	approach	based	on	gene-set	enrichment	analysis.	We	used	Ingenuity	Pathway	Analysis	(IPA)	(www.ingenuity.com)	to	identify	pathway	enrichment	among	genes	associated	with	different	neurological	traits	for	canonical	pathways.	Canonical	pathways	are	structured	pathways.	Data	from	the	different	phenotypes	were	integrated	and	subjected	to	network	analysis	via	IPA	to	identify	pathway	enrichment.	Enriched	networks	are	ordered	by	–log	p-value,	based	on	a	Fisher	Exact	test	p-value.37	For	each	disease	we	included	SNPs	with	a	p-value	<5x10-4,	and	excluded	SNPs	in	the	MHC	region	due	to	the	long	stretches	of	LD	in	this	region.	We	also	performed	a	pathway	analysis	looking	at	KEGG	pathways	using	enrichr	38,39	in	order	to	compare	results.	
	
Results	There	is	limited	evidence	of	pairwise	genetic	correlation	among	the	four	diseases	using	cross-trait	LD	score	regression.	The	lack	of	an	AD-PD	pairwise	correlation	has	already	been	reported,	as	well	as	between	AD-MS	and	PD-MS.40	We	also	found	no	statistically	significant	evidence	for	genetic	correlation	between	ALS-AD	(0.2,	p=	0.08),	ALS-PD	(-0.08,	p=0.01),	and	ALS-MS	(-0.04,	p=0.7).		For	the	grouped	cell-type	analysis	from	Finucane	et	al.,31	the	most	significant	enrichment	was	seen	for	the	immune/hematopoietic	category	for	MS	(10.1,	p=	3.8	x	10-13),	confirming	the	recognized	role	of	the	immune	system	in	this	disease.	This	category	was	also	significantly	enriched	for	heritability	of	AD	(5.5,	p=	2.4	x	10-7),	in	addition	to	liver	(10.5,	p=	1.1	x	10-5),	and	these	AD	signals	remained	significant	even	after	the	removal	of	APOE	(chr19:	44905754-44909393)	(5.5,	p=	2.5	x	10-7	and	10.5,	p=	1.1	x	10-5	respectively).	For	ALS	and	PD,	there	were	no	significantly	enriched	functional	categories	(Fig	1).		At	the	tissue	level,	none	of	the	enrichments	were	significant	for	the	brain	annotations.	The	most	suggestive	signal	was	for	the	inferior	temporal	region	in	AD	(4.9,	p=	6.6	x	10-4).			For	the	cell-specific	immune	annotations	assessed	relating	to	both	the	innate	and	adaptive	immune	systems,	there	was	significant	enrichment	for	MS	heritability	and	to	a	lesser	extent	for	AD	and	PD.	There	was	no	enrichment	of	heritability	for	ALS,	the	smallest	dataset	in	our	study	(Supplementary	Table	1,	Fig	2).		Strong	MS	signals	for	heritability	enrichment	were	found	in	all	immune	cell	categories,	
including	both	adaptive	and	innate	cell	types.		Significant	AD	signals	were	found	in	all	immune	cell	categories	except	for	the	non-T-cell/non-B-cell	component	of	the	adaptive	immune	system.	For	PD,	only	two	annotations	passed	the	multiple	testing	threshold:	primary	T	helper	cells	PMA-I	stimulated	and	primary	T	regulatory	cells	from	peripheral	blood	(5.2	and	5.4,	respectively,	p=	0.0002	for	both),	but	several	other	immune	annotations	were	suggestive.			Consistent	with	previous	applications	of	the	LD	score	regression	method,	we	included	the	annotations	separately	in	the	regression	model.	This	means	that	that	enrichments	in	innate	immune	cells	could	in	principle	be	due	to	overlap	in	annotation	with	adaptive	immune	cell-types,	and	vice	versa.	To	assess	this	issue,	we	determined	the	degree	of	annotation	overlap	between	all	pairs	of	immune	cell	types	in	our	study	(Supplementary	Table	2).		We	found	the	degree	of	overlap	between	innate	versus	adaptive	cells	ranged	from	0.06%	(for	CD14:	a	marker	for	monocytes	versus	CD20:	a	marker	of	B	lymphocytes)	to	12%	(for	peripheral	blood	mononuclear	primary	cell	versus	primary	T	cells	from	cord	blood),	suggesting	a	large	degree	of	independence	between	adaptive	and	innate	cell	marks.	To	further	investigate	this	issue,	we	carried	out	deeper	analyses	on	a	representative	adaptive	cell	type	(primary	T	cells	from	cord	blood)	and	a	representative	innate	cell	type	(CD15:	a	marker	for	neutrophils),	both	of	which	displayed	strong	heritability	enrichment	signals	in	AD.		The	annotation	overlap	between	these	two	cell	types	was	6.7%	(Supplementary	Table	2).		When	we	included	both	annotations	simultaneously	in	the	LD	score	regression	model,	we	found	that	both	cell	lines	remained	significantly	enriched	for	MS	(22.0,	p=	7.4	x	10-20	and	17.2,	2.3	x	10-5,	respectively).	Similarly,	for	AD,	both	cell	lines	remained	significantly	enriched	(8.7,	p=	1.7	x	10-7	and	14.3,	p=	7.3	x	10-6,	respectively).	Neither	of	these	cell	lines	had	reached	significance	for	PD	or	ALS	in	the	models	where	they	were	inputted	separately,	nor	were	they	significant	when	included	simultaneously	into	the	model.	The	enrichment	results	for	primary	T	cells	from	cord	blood	and	CD15	when	included	simultaneously	in	the	model	for	PD	are	4.9,	p=	1.1	x	10-3	and	7.0,	p=	5.2	x	10-3,	respectively;	and	for	ALS	3.5,	p=	0.03	and	3.1,	p=	0.37	respectively.	Overall,	these	analyses	provided	us	with	re-assurance	that	we	were	detecting	independent	signals	in	adaptive	versus	innate	immune	cell	types.		Our	heritability	enrichment	analysis	within	brain-related	and	immune-related	gene	sets	also	provided	strong	evidence	for	a	signal	in	the	immune	gene	set,	and	not	in	the	brain	gene	set	(Supplementary	Table	1).	As	expected,	the	strongest	immune	gene	signal	was	for	MS	(1.6,	p=	4.6x10-14).	We	have	previously	reported	the	enrichment	of	this	immune	gene	list	in	the	same	MS	dataset,	using	an	earlier	version	of	LD	score	regression.32	The	immune	gene	list	was	also	enriched	for	heritability	in	AD	(5.2,	p=	4.8	x	10-4),	and	the	effects	in	PD	and	ALS	were	suggestive	but	would	not	survive	multiple	testing	correction	(4.5,	p=	0.02	and	2.5,	p=	0.03,	respectively).	The	brain	gene	list	was	not	significantly	enriched	in	any	of	the	neurodegenerative	diseases	assessed	(among	the	other	three	diseases	enrichment	ranges	from	0.9	to	1.9,	p	>0.04	for	all	three).			
Finally,	we	compared	the	above	results	to	an	Ingenuity	IPA	pathway	enrichment	analysis,	both	within	canonical	pathways	(Supplementary	Table	3a)	and	within	diseases/biological	functions	including	cancer-related	functions	(Supplementary	
Table	3b).	We	also	compared	our	results	to	an	enrichr	pathway	enrichment	analysis	(Supplementary	Table	3c).	Remarkably,	for	the	IPA	canonical	pathway	analysis,	all	the	significant	pathways	save	one	("Aldosterone	Signaling	in	Epithelial	Cells")	were	found	to	be	connected	to	either	adaptive	or	innate	immune	response.	Specific	examples	included:	in	MS	(e.g.	T	helper	cell	differentiation,	role	of	macrophages,	fibroblasts	and	endothelial	cells	in	RA,	B	cell	receptor	signaling,	dendritic	cell	maturation,	PI3K	signaling	in	B	lymphocytes,	CD40	signaling;	PKCθ	signaling	in	T	lymphocytes,	NF-κB	activation	by	viruses);	in	PD	(e.g.	dendritic	cell	maturation	–	shared	with	MS,	graft-versus-host	disease	signaling,	altered	T	cell	and	B	cell	signaling	in	rheumatoid	arthritis);	in	AD	(IL-8	signaling,	IL-12	signaling	and	production	in	macrophages,	Fc	epsilon	RI	signaling,	Fcγ	receptor-mediated	phagocytosis	in	macrophages	and	monocytes,	role	of	pattern	recognition	receptors	in	recognition	of	bacteria	and	viruses,	natural	killer	cell	signaling);	and	in	ALS	(e.g.	NF-κB	signaling).	The	value	of	the	IPA	method	was	also	demonstrated	in	providing	significant	signals	for	other	pathways	previously	implicated	in	the	pathogenesis	of	AD,	including	CREB	signaling	in	neurons,41	neuregulin	signaling,	and	ErbB	signaling.42	For	the	IPA	diseases/biological	functions	analysis,	various	cancers	came	up	as	most	strongly	significant	for	all	the	disorders.	Cancer	has	been	shown	to	be	correlated	with	multiple	immune	disorders	43,	and	there	is	evidence	of	cancer	and	neurodegenerative	disorders,	such	as	PD,	sharing	common	pathways.44	The	enrichr	analysis	revealed	many	significant	immune-related	pathways,	in	line	with	the	IPA	canonical	pathways	analysis.		
Discussion	Multiple	lines	of	evidence	suggest	a	significant	contribution	of	variants	exhibiting	functional	marks	for	chromatin	accessibility	(i.e.	histone	marks,	DNase	I	hypersensitive	sites)	in	immune	cell	types	to	the	heritability	of	two	neurodegenerative	diseases,	namely	AD	and	PD.	Annotations	from	immune	cells	are	most	significantly	enriched	for	the	heritability	of	MS,	a	known	autoimmune	disease	which	acted	as	a	positive	control	in	our	investigations.17	Immune	annotations	are	also	consistently	enriched	but	to	a	lesser	degree	for	AD	(with	involvement	from	both	the	innate	and	adaptive	immune	systems),	and	some	cell-specific	immune	annotations	(T-cells)	were	significantly	enriched	for	PD.	A	lack	of	results	from	the	ALS	dataset	could	be	attributed	to	this	dataset	being	smaller	than	the	other	datasets	investigated	(Table	1).	These	results	provide	further	support	for	the	neuroinflammatory	hypothesis	of	neurodegenerative	disease,15,16	and	highlight	the	potential	utility	of	immune	modulating	agents,	such	as	those	currently	used	in	MS	for	the	treatment	of	AD	and	PD.	However,	one	needs	to	be	cautious	with	interpreting	these	cell/tissue-type	specific	results	in	the	absence	of	functional	and	other	studies.		We	note	that	if	we	correct	for	the	17	GWASs	assessed	in	Finucane	et	al.31	as	well	as	the	four	GWASs	we	assessed	here	for	the	10	cell-type	groups	((17+4)	x	10	=	210	
hypotheses	tested),	both	the	immune/hematopoietic	and	liver	categories	remain	significant	for	AD.			The	role	of	the	immune	system	in	AD	pathogenicity	has	been	previously	shown22,25	and	previous	pathway	analysis	of	the	AD	GWAS	we	assessed	here	showed	enrichment	in	immune-related	pathways.24	Findings	are	strongest	for	the	innate	immune	response,	for	instance	association	with	the	TREM2	gene,	which	in	brain	cells	are	primarily	expressed	on	microglia.45,46	Our	findings	further	support	the	role	of	immune	variation	in	AD	susceptibility.	Interestingly,	using	LD	score	regression,	AD	was	found	to	be	not	significantly	correlated	with	a	variety	of	immune	diseases.34	This	lack	of	correlation	could	be	because	when	considering	the	entire	genome	the	signal	coming	from	the	correlated	loci	between	the	diseases	is	diluted,	or	the	immune	variants	involved	in	AD	are	different	from	those	involved	in	other	immune	diseases.	Microglia,	the	main	immune	cell	type	in	the	brain,	have	a	different	developmental	trajectory	separate	from	the	peripheral	immune	system.47	The	unique	mechanisms	of	immune	surveillance	in	the	brain	48,49also	makes	immune	diseases	of	the	brain	biologically	distinct	to	peripheral	immune	diseases,	but	there	is	much	evidence	that	disruption	of	the	brain’s	immune	surveillance	is	critical	to	the	“vicious	cycle”	of	worsening	pathology	seen	in	neurodegeneration.50	Our	analysis	suggests	a	predominantly	epigenomic	mechanism	for	immune	dysregulation	in	neurodegenerative	disease,	and	if	confirmed	this	may	be	of	therapeutic	relevance,	as	many	drugs	are	known	to	act	through	this	mechanism.	Some,	such	as	histone	deacetylase	inhibitors,	could	potentially	be	efficacious	in	neurodegenerative	diseases.51		Functional	marks	from	liver	were	also	enriched	for	the	heritability	of	AD.	This	result	agrees	with	findings	in	the	literature	of	the	contribution	of	lipid	metabolism	through	liver	X	receptors	(LXR)	to	the	initiation	and	progression	of	this	disease.52,53		Canonical	pathway	analysis	showed	enrichment	of	AD	associations	in	CREB	signaling	in	neurons,	and	also	IL8	and	IL12	signaling	(which	are	CREB	regulated),	supporting	the	immune	hypothesis	in	AD,	and	pointing	to	interleukin	signaling	as	a	potential	CREB-responsive	mechanism.54		
	Our	results	do	not	provide	statistically	significant	evidence	that	variants	overlapping	with	functional	annotations	from	the	brain	contribute	excessively	to	the	heritability	of	neurodegenerative	diseases.	The	brain	doubtless	plays	an	important	role	in	the	genetic	aetiology	of	these	diseases.	The	lack	of	brain	annotation	enrichment	could	be	due	to	data	being	based	on	few	samples	for	the	brain.		Furthermore,	the	brain	is	a	very	heterogeneous	tissue.	Data	from	brain	regions	contain	a	mixture	of	different	cell	types	such	as	microglia	and	neurons.	Single	cell	sampling	may	reduce	this	heterogeneity	in	the	future.55	This	analysis	should	be	revisited	as	brain	annotation	information	improves.	
	
In	summary,	our	results	suggest	a	significant	contribution	of	variants	that	exhibit	chromatin	accessibility	marks	in	immune	cells	to	the	heritability	of	two	neurodegenerative	diseases,	namely	AD	and	PD.		
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Figures		
	
Fig	1.	Enrichment	of	cell-type	groups	as	used	in	Finucane	et	al.	2015.	The	black	dashed	lines	at	-log10(P)	=	2.9	is	the	cutoff	for	Bonferroni	significance.		
Fig	2.	Enrichment	of	immune	cell	annotations.	The	black	dashed	lines	at	-log10(P)	=	3.6	is	the	cutoff	for	Bonferroni	significance.	White	bars=	tissue;	purple	bars=	CD34	(marker	of	immature	hematopoietic	cells	-	not	strictly	adaptive	or	innate);	light	blue	bars=	marker	of	T	cells;	dark	blue	bar=	marker	of	B	cells;	royal	blue	bars=	cells	of	the	adaptive	immune	system;	pink	bars=	cells	of	the	innate	immune	system			
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Table	1.	Description	of	the	GWASs	summary	statistics		Neurodegenerative	disease	 PMID	 Cases	 Controls	 Cohorts	Parkinson’s	disease	(PD)	 25064009		 13,708	 95,282	 15	
Alzheimer’s	disease	(AD)	 24162737	 17,008	 37,154	 19	Amyotrophic	lateral	sclerosis	(ALS)	 24256812	 7,177	 8,393	 8	Multiple	sclerosis	(MS)	 21833088		 9,772	 17,376	 23	
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Supplementary	Table	1.	Annotation	enrichment	results.	Red	cells	mark	enrichment	that	survived	Bonferroni	correction.		
	
Supplementary	Table	2.	Overlap	among	chromatin	accessibility	annotations	for	immune	cells.	The	main	diagonal	shows	genome	coverage	(base	pairs)	for	that	cell	type.	The	upper	off-diagonal	shows	the	overlap	coverage	(base	pairs)	for	that	cell-type-pair.	The	lower	off-diagonal	shows	the	proportion	of	overlap	coverage	for	that	cell-type	pair.	
	
Supplementary	Table	3.	[a]	Ingenuity	Pathway	Analysis	(IPA)	results	for	canonical	pathways.	Red	cells	mark	enrichment	that	survived	Bonferroni	correction.	[b]	Ingenuity	Pathway	Analysis	(IPA)	results	for	cancer-related	functions.	Red	cells	mark	enrichment	that	survived	Bonferroni	correction.		[c]	enrichr	KEGG	pathway	results.	Multiplication	of	the	p-value	computed	using	the	Fisher	exact	test	with	the	z-score	of	the	deviation	from	the	expected	rank	as	described	in	the	enrichr	paper.38	
